108 related articles for article (PubMed ID: 23047570)
21. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
[TBL] [Abstract][Full Text] [Related]
22. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.
Garrone O; Crosetto N; Lo Nigro C; Catzeddu T; Vivenza D; Monteverde M; Merlano M; Feola M
Cardiovasc Toxicol; 2012 Jun; 12(2):135-42. PubMed ID: 22189487
[TBL] [Abstract][Full Text] [Related]
23. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
Florescu M; Magda LS; Enescu OA; Jinga D; Vinereanu D
J Am Soc Echocardiogr; 2014 Jan; 27(1):83-92. PubMed ID: 24268372
[TBL] [Abstract][Full Text] [Related]
24. Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy.
Klein R; Nadouri D; Osler E; Johnson C; Dent S; Dwivedi G
Nucl Med Commun; 2019 Jan; 40(1):22-29. PubMed ID: 30418380
[TBL] [Abstract][Full Text] [Related]
25. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
[TBL] [Abstract][Full Text] [Related]
26. Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy.
Foulkes SJ; Howden EJ; Bigaran A; Janssens K; Antill Y; Loi S; Claus P; Haykowsky MJ; Daly RM; Fraser SF; LA Gerche A
Med Sci Sports Exerc; 2019 Aug; 51(8):1573-1581. PubMed ID: 30829962
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.
Truong SR; Barry WT; Moslehi JJ; Baker EL; Mayer EL; Partridge AH
Oncologist; 2016 Jun; 21(6):666-70. PubMed ID: 27107002
[TBL] [Abstract][Full Text] [Related]
28. [Determination of ejection fraction and left ventricular fraction using isotopic ventriculography and bidimensional echocardiography. Comparison with contrast ventriculography].
Casáns Tormo I; Gómez Aldaravi R; Bodí Peris V; Sanchis Forés J; Ciudad Platero J; Insa Pérez L; Manjón Soriano J
Rev Esp Cardiol; 1998; 51 Suppl 1():10-8. PubMed ID: 9549395
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of peak filling rate for the early identification of daunorubicin cardiotoxicity].
Trappolini M; Matteoli S; Galli V; Grego V
G Ital Cardiol; 1988 Jan; 18(1):55-60. PubMed ID: 3384249
[TBL] [Abstract][Full Text] [Related]
30. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Petretta M; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 May; 84(5):1518-23. PubMed ID: 10323372
[TBL] [Abstract][Full Text] [Related]
31. Left ventricular systolic and diastolic function measurements using an ambulatory radionuclide monitor: effects of different time averaging on accuracy.
Pace L; Cuocolo A; Stefano ML; Nappi A; Nicolai E; Imbriaco M; Trimarco B; Salvatore M
J Nucl Med; 1993 Sep; 34(9):1602-6. PubMed ID: 8355081
[TBL] [Abstract][Full Text] [Related]
32. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of adriamycin cardiotoxicity using equilibrium radionuclide ventriculography. I. Results at rest].
Knesewitsch P; Göldel NH; Fritsch S; Moser E
Nuklearmedizin; 1987 Oct; 26(5):206-11. PubMed ID: 3432064
[TBL] [Abstract][Full Text] [Related]
34. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
35. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab-related cardiac events in the treatment of early breast cancer.
Fried G; Regev T; Moskovitz M
Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507
[TBL] [Abstract][Full Text] [Related]
37. Cardiac Function After Multimodal Breast Cancer Therapy Assessed With Functional Magnetic Resonance Imaging and Echocardiography Imaging.
Heggemann F; Grotz H; Welzel G; Dösch C; Hansmann J; Kraus-Tiefenbacher U; Attenberger U; Schönberg SO; Borggrefe M; Wenz F; Papavassiliu T; Lohr F
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):836-44. PubMed ID: 26530752
[TBL] [Abstract][Full Text] [Related]
38. The relationship between plasma hyaluronan levels and anthracycline-related cardiotoxicity in breast cancer patients.
Inanc MT; Karadavut S; Aytekin M; Duran AO; Derya M; Akpek M; Sahin O; Kalay N; Karaca H; Ozkan M; Inanc M
Int J Cardiol; 2016 Sep; 218():246-251. PubMed ID: 27236123
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of left ventricular diastolic function by radionuclide ventriculography in patients with coronary artery disease.
Spaić S; Marković S; Odavić M; Angelkov L; Spaić R
Med Pregl; 1993; 46 Suppl 1():11-3. PubMed ID: 8569592
[TBL] [Abstract][Full Text] [Related]
40. [Clinical observation on the anthracyclines-induced cardiotoxicity in patients with early-stage breast cancer].
Hu GF; Fu HX; Ma JF; Hu MF; Zhao ZN; Hu C; Yang J
Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Dec; 46(12):987-992. PubMed ID: 30572405
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
